Publications

1:2011 Dec 16,

Does anti-tnf therapy cause any change in platelet activation in ankylosing spondylitis patients? : A comparative study.

Recently, it has been reported that ankylosing spondylitis (AS) was characterised by endothelial dysfunction and the development of atherosclerotic complications. In this study, we evaluated platelet ...

2:2011 Dec 13,

Depth and volume of resorption induced by osteoclasts generated in the presence of RANKL, TNF-alpha/IL-1 or LIGHT.

Rheumatoid arthritis (RA) is associated with pathological bone destruction mediated by osteoclasts. Although RANKL has been reported as a crucial factor for osteoclastogenesis, several other factors i...

3:Aliment. Pharmacol. Ther.2012 Jan,35(2)

Anti-TNF associated psoriasis: authors' reply.

...

4:Aliment. Pharmacol. Ther.2012 Jan,35(2)

Anti-TNF associated psoriasis.

...

5:2011 Dec 15,

Synthesis of lipophilic genistein derivatives and their regulation of IL-12 and TNF-? in activated J774A.1 cells.

Genistein modulates inflammatory responses in part by reducing the production of the pro-inflammatory cytokines IL-12, TNF-? and nitric oxide (NO), by activated macrophages in response to lipopolysacc...

7:2011 Dec 16,

De-ubiquitinating protease USP2a targets RIP1 and TRAF2 to mediate cell death by TNF.

Components of the TNFR1 complex are subject to dynamic ubiquitination that impacts on their effects as signalling factors. We have found that the ubiquitin-specific protease USP2a has a pivotal role i...

8:2011 Dec 16,13(6)

Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-TNF.

ABSTRACT: INTRODUCTION: As a group Rheumatoid arthritis (RA) patients exhibit increased risk of infection, and those treated with anti-TNF therapy are at further risk. This increased susceptibility m...

9:J. Peripher. Nerv. Syst.2011 Dec,16(4)

The ology of neuropathy: an integrative review of the role of neuroinflammation and TNF-? axonal transport in neuropathic pain.

This 2011 Peripheral Nerve Society plenary lecture reviews the role of axonal transport in neuroimmune communication following peripheral nerve injury, linking focal changes in Schwann cell activation...

11:Int J Mol Epidemiol Genet2011,2(4)

The influence of tumour necrosis factor- ? (TNF-?) on amyloid-? (A?)-degrading enzymes in vitro.

Pro-inflammatory cytokines, such as tumour necrosis factor-? (TNF-?), are increased in serum and CSF in Alzheimer's disease (AD). We investigated the effect of TNF-? on gene and protein expression lev...

12:Anticancer Res.2011 Dec,31(12)

Resveratrol Reduces TNF-?-induced U373MG Human Glioma Cell Invasion through Regulating NF-?B Activation and uPA/uPAR Expression.

High invasiveness of glioma cells is one of the reasons that patients with malignant glioma have a poor prognosis. Resveratrol, a plant compound abundant in the peel of grapes, has been suggested as a...

13:2011 Dec 23,

Mitogen-activated protein kinase phosphatase-1 inhibits myocardial TNF-alpha expression and improves cardiac function during endotoxemia.

Aims Myocardial tumor necrosis factor-? (TNF-?) expression induces cardiac dysfunction in endotoxemia. The aim of this study was to investigate the role of mitogen-activated protein kinase phosphatase...

14:2011 Dec 16,

The calcineurin B subunit induces TNF-related apoptosis-inducing ligand (TRAIL) expression via CD11b-NF-?B pathway in RAW264.7 macrophages.

We showed previously that calcineurin B subunit (CnB) could inhibit S180 solid tumor growth in mice and prolong the survival of mice bearing H22 ascites tumors, but the underlying antitumor mechanism ...

15:2011 Dec 16,

Both the Fab and Fc domains of IgG are essential for ROS emission from TNF-?-primed neutrophils by IVIG.

Intravenous immunoglobulin (IVIG) is currently a very important therapeutic used for not only infectious diseases, but also for autoimmune diseases such as idiopathic thrombocytopenic purpura (ITP). U...

16:Clin. Dev. Immunol.2012,2012

Characterization of Chronic Cutaneous Lesions from TNF-Receptor-1-Deficient Mice Infected by Leishmania major.

Leishmania major-infected TNF receptor 1 deficient (TNFR1 KO) mice resolve parasitism but fail to resolve lesions, while wild-type mice completely heal. We investigated the cell composition, cytokine ...

17:2011 Dec 28,

Monocyte to macrophage differentiation-associated (MMD) positively regulates ERK and Akt activation and TNF-? and NO production in macrophages.

Macrophage activation is modulated by both environmental cues and endogenous programs. In the present study, we investigated the role of a PAQR family protein, monocyte to macrophage differentiation-a...

18:2011 Dec 19,

Osteoprotegerin (OPG) and TNF-related apoptosis-inducing ligand (TRAIL) levels in malignant and benign pericardial effusions.

OBJECTIVES: Osteoprotegerin (OPG) is a regulator of bone and vascular homeostasis and acts as a decoy receptor for proapoptotic TNF-related apoptosis-inducing ligand (TRAIL). DESIGN AND METHODS: We as...

19:J Drugs Dermatol2012 Jan 1,11(1)

Transient Improvement in Chronic Psoriasis After Treatment of TNF-? Blocker Induced Disseminated M. Tuberculosis Infection.

Improvement in psoriasis after treatment of reactivated latent tuberculosis following initiation of TNF-? inhibitor therapy has yet to be described in the literature. The authors present a case of tra...

20:2011 Dec 30,

Influence of Maternal Hyperglycemia on IL-10 and TNF-? Production: The Relationship with Perinatal Outcomes.

AIMS: This study was conducted to evaluate maternal and placental concentrations of interleukin 10 (IL-10) and tumor necrosis factor-alpha (TNF-?) in pregnant women with glycemic...

Protein Name:TNF-α (Mutant)
Gene Name:TNF TNFA TNFSF2

Cat.No.Price/SizeQtyCart
C036

Recombinant Human Recombinant Human TNF Alpha, Tumor Necrosis Factor Alpha | Novoprotein
(CatNo. C036)

Recombinant Human TNF Alpha, Tumor Necrosis Factor-α/TNF-α Mutant produced in E. coli is a single non-glycosylated polypeptide chain containing 151 amino acids with a molecular mass of 16,886 Daltons.

Recombinant Human TNF Alpha: Tumor Necrosis Factor-α (TNF-α) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-α while cells that express CD8 secrete little or no TNF-α. Synthesis of TNF-α can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-α has been limited by the proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-α mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF-α that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-α, which binds to both murine TNF receptors. Based on these results, many TNF-α mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-α High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.